Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Cortecs/Osteometer BioTech agreement

This article was originally published in The Gray Sheet

Executive Summary

Cortecs/Osteometer BioTech agreement: U.K.-based oral drug delivery firm Cortecs inks a development deal with Danish diagnostics firm Osteometer BioTech A/S to develop a whole blood, point-of-care diagnostic product for the detection of collagen breakdown, an indicator of osteoporosis. Cortecs, calling the deal a "profit-sharing agreement," says that the development effort will combine its rapid diagnostic technologies with Osteometer's Cross-laps bone resorption marker technology. The companies will jointly develop the product, with clinical testing coordinated by The Center for Clinical and Basic Research in Denmark. Cortecs will manufacture the finished product, retain distribution rights for the U.K. and Australia and select distributors for other markets "from international corporations involved in the management of osteoporosis"...

You may also be interested in...

Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

Generics Approvals Will Decline, US FDA Predicts, But Supplement Work May Grow

With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts